Iptacopan治疗IgA肾病长期疗效与安全性
基于APPLAUSE-IgAN三期试验及其开放标签扩展项目,评估补体因子B抑制剂iptacopan治疗IgA肾病的长期疗效与安全性。结果显示,iptacopan持续减缓eGFR下降并降低蛋白尿,从安慰剂转换后eGFR斜率改善,未发现新安全信号。
要点
- iptacopan治疗48个月总eGFR斜率为-3.49 ml/min/1.73m²/年,蛋白尿降幅持续。
- 安慰剂组转换iptacopan后eGFR斜率从-5.29改善至-2.11 ml/min/1.73m²/年。
- 长达5年安全性数据与已知特征一致,未见新安全信号。
核心结论
- 长期iptacopan治疗持续减缓eGFR下降并降低蛋白尿,从安慰剂转换后亦观察到改善,未发现新安全信号。
研究设计与样本
- APPLAUSE-IgAN三期试验及其开放标签扩展项目(REP),REP中194例iptacopan组和174例安慰剂组患者接受口服iptacopan 200mg每日两次。
主要发现
- iptacopan治疗长达48个月的总年化eGFR斜率为-3.49 ml/min/1.73m²/年(95%CI -4.17, -2.80)。
- UPCR-FMV从基线至48个月的几何均值比为0.61(95%CI 0.50, 0.75),蛋白尿降低持续。
- 安慰剂组转换前24个月总eGFR斜率为-5.29 ml/min/1.73m²/年(95%CI -6.09, -4.49),转换后24个月改善至-2.11 ml/min/1.73m²/年(95%CI -3.08, -1.13)。
- 转换后UPCR-FMV至第48个月几何均值比为0.74(95%CI 0.59, 0.91)。
- 安全性随访长达5年(中位治疗时长29.9个月),与已知特征一致。
临床怎么用
- iptacopan可作为IgA肾病长期治疗选择,持续减缓肾功能下降并降低蛋白尿。
局限性
- 开放标签扩展研究,无对照,疗效分析未纳入二期试验患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Iptacopan, a factor B inhibitor, targets alternative complement pathway overactivation, a key driver of glomerular inflammation in IgA nephropathy. In the phase 3 APPLAUSE-IgAN trial (NCT04578834), iptacopan significantly slowed kidney function decline versus placebo over 24 months (difference in total estimated glomerular filtration rate [eGFR] slope: 3.02 ml/min per 1.73 m2 per year [95% confidence interval (CI) 2.02, 4.01; P < 0.001]). METHODS: Patients who completed APPLAUSE-IgAN or the phase 2 iptacopan trial (NCT03373461) could enter an open-label rollover extension program (REP) (NCT04557462). Patients in this REP receive oral iptacopan 200 mg twice daily alongside supportive care. Patients from the phase 2 trial were not included in efficacy analyses. RESULTS: Overall, 194 and 174 patients from the APPLAUSE-IgAN iptacopan and placebo arms, respectively, entered the REP. In patients who received iptacopan for up to 48 months, the total annualized eGFR slope was -3.49 ml/min per 1.73 m2 per year (95% CI -4.17, -2.80). Urine protein-to-creatinine ratio from first morning void (UPCR-FMV) reduction was sustained through 48 months with iptacopan (geometric mean ratio to baseline: 0.61 [95% CI 0.50, 0.75]). Before receiving iptacopan, the total eGFR slope over 24 months in APPLAUSE-IgAN placebo arm patients who entered the REP was -5.29 ml/min per 1.73 m2 per year (95% CI -6.09, -4.49). After switching to iptacopan, the total eGFR slope improved to -2.11 ml/min per 1.73 m2 per year (95% CI -3.08, -1.13) over the next 24 months. UPCR-FMV decreased after switching (geometric mean ratio to baseline at month 48: 0.74 [95% CI 0.59, 0.91]). Long-term safety up to 5 years (median treatment duration: 29.9 months) was consistent with the known profile of iptacopan. CONCLUSIONS: Long-term treatment with iptacopan led to sustained slowing in eGFR decline and proteinuria reduction that were also observed after switching from placebo. No new safety signals were observed. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study numbers NCT04578834 (APPLAUSE-IgAN), NCT03373461 (phase 2 trial of iptacopan in IgAN), and NCT04557462 (rollover extension program).
引用
- Rovin BH, Trimarchi H, Maes B, et al. Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy. Kidney Int. 2026. PMID: 42909451. doi:10.1016/j.kint.2026.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。